Compare Manchester United PLC (MANU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Tango Therapeutics Inc. — how do they compare? Manchester United PLC trades at $20.68 (market cap $3.55B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Manchester United PLC and Tango Therapeutics Inc. are close in size by market cap, and Manchester United PLC pays a 1.26% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Tango Therapeutics Inc. for 0 Days on average.
| MANU | TNGX | |
|---|---|---|
Market Cap | $3.55B | $3.74B |
Volume | 311,271 | 3,438,781 |
Sector | Media | Health |
52-Week High | $24.19 | $32.90 |
52-Week Low | $15.20 | $7.50 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $4.38B | $2.76B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $21.08, up 1.2% with a bullish technical signal despite negative profitability metrics. The stock shows mixed earnings performance with recent beats but negative net income margins. Revenue reached $666.51M in 2025, though the company continues to post losses. Analyst sentiment is divided with 40% buy ratings, while technical indicators suggest potential near-term support at $21.
The investment case hinges on franchise valuation upside versus operational challenges. While trading at a discount to Forbes' $7.2B valuation estimate, persistent losses and high debt levels present significant risks. Champions League qualification offers revenue potential, but profitability remains elusive amid competitive pressures in European football.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
